BACKGROUND: Osteosarcoma is the most common primary bone tumor in adolescents associated with skeletal development. The molecular pathogenesis of osteosarcoma has not been completely determined, although many molecular alterations have been found in human osteosarcomas and cell lines. QUESTIONS/PURPOSES: We questioned whether (1) we could identify gene expression in osteosarcoma specimens that differs from normal osteoblasts and mesenchymal stem cells and (2) this would provide clues to the molecular pathogenesis of osteosarcoma? METHODS: The whole-genome transcriptional profiles of osteosarcomas, including two primary biopsy specimens, two cell lines, two xenografts derived from patient specimens, and one from normal osteoblasts and from mesenchymal stem cells, respectively, were quantitatively measured using serial analysis of gene expression. A statistical enrichment was performed, which selects the common genes altered in each of the osteosarcomas compared with each of the normal counterparts independently. RESULTS: Sixty (92%) of 65 total genes that were at least twofold downregulated in osteosarcoma compared with osteoblasts and mesenchymal stem cells, could be classified in four categories: (1) seven genes in the insulin–like growth factor (IGF) signaling axis, including three of the IGF-binding proteins (IGFBP) and three of the IGFBPrelated proteins (IGFBPrP); (2) eight genes in the transforming growth factor-b (TGF-b)/bone morphogenetic protein (BMP) signaling cascade; (3) 39 genes encoding cytoskeleton and extracellular matrix proteins that are regulated by TGF-b/BMPs; and (4) six genes involved in cell cycle regulation, including tumor suppressors TP63 and p21. CONCLUSIONS: Based on these transcriptional profiles, a coordinated theme of clustered gene deregulation in osteosarcoma has emerged. Cell proliferation driven by the IGF axes during bone growth is unrestrained owing to downregulation of IGFBPs and cell cycle regulators. Tumor cells may be maintained in an undifferentiated state secondary to impaired TGF-b/BMP signaling. This wellpreserved pattern suggests that the alterations in the signaling axes of IGF-1 and TGF-b, in concert with cell cycle regulators, may be an important pathogenic basis of osteosarcoma. CLINIC RELEVANCE: This study provides a possible molecular basis of pathogenesis of osteosarcoma. This may help to develop new therapeutic targets and strategy for this disease. Preclinical and subsequently clinical testing of inhibitors of the IGF-1 and TGF pathways would be warranted.
BACKGROUND:Osteosarcoma is the most common primary bone tumor in adolescents associated with skeletal development. The molecular pathogenesis of osteosarcoma has not been completely determined, although many molecular alterations have been found in humanosteosarcomas and cell lines. QUESTIONS/PURPOSES: We questioned whether (1) we could identify gene expression in osteosarcoma specimens that differs from normal osteoblasts and mesenchymal stem cells and (2) this would provide clues to the molecular pathogenesis of osteosarcoma? METHODS: The whole-genome transcriptional profiles of osteosarcomas, including two primary biopsy specimens, two cell lines, two xenografts derived from patient specimens, and one from normal osteoblasts and from mesenchymal stem cells, respectively, were quantitatively measured using serial analysis of gene expression. A statistical enrichment was performed, which selects the common genes altered in each of the osteosarcomas compared with each of the normal counterparts independently. RESULTS: Sixty (92%) of 65 total genes that were at least twofold downregulated in osteosarcoma compared with osteoblasts and mesenchymal stem cells, could be classified in four categories: (1) seven genes in the insulin–like growth factor (IGF) signaling axis, including three of the IGF-binding proteins (IGFBP) and three of the IGFBPrelated proteins (IGFBPrP); (2) eight genes in the transforming growth factor-b (TGF-b)/bone morphogenetic protein (BMP) signaling cascade; (3) 39 genes encoding cytoskeleton and extracellular matrix proteins that are regulated by TGF-b/BMPs; and (4) six genes involved in cell cycle regulation, including tumor suppressors TP63 and p21. CONCLUSIONS: Based on these transcriptional profiles, a coordinated theme of clustered gene deregulation in osteosarcoma has emerged. Cell proliferation driven by the IGF axes during bone growth is unrestrained owing to downregulation of IGFBPs and cell cycle regulators. Tumor cells may be maintained in an undifferentiated state secondary to impaired TGF-b/BMP signaling. This wellpreserved pattern suggests that the alterations in the signaling axes of IGF-1 and TGF-b, in concert with cell cycle regulators, may be an important pathogenic basis of osteosarcoma. CLINIC RELEVANCE: This study provides a possible molecular basis of pathogenesis of osteosarcoma. This may help to develop new therapeutic targets and strategy for this disease. Preclinical and subsequently clinical testing of inhibitors of the IGF-1 and TGF pathways would be warranted.
Authors: Michael Overholtzer; Pulivarthi H Rao; Reyna Favis; Xin-Yan Lu; Michael B Elowitz; Francis Barany; Marc Ladanyi; Richard Gorlick; Arnold J Levine Journal: Proc Natl Acad Sci U S A Date: 2003-09-12 Impact factor: 11.205
Authors: Wilson A Silva; Dimas T Covas; Rodrigo A Panepucci; Rodrigo Proto-Siqueira; Jorge L C Siufi; Dalila L Zanette; Anemari R D Santos; Marco A Zago Journal: Stem Cells Date: 2003 Impact factor: 6.277
Authors: Yves A DeClerck; Arthur M Mercurio; M Sharon Stack; Harold A Chapman; Mary M Zutter; Ruth J Muschel; Avraham Raz; Lynn M Matrisian; Bonnie F Sloane; Agnes Noel; Mary J Hendrix; Lisa Coussens; Martin Padarathsingh Journal: Am J Pathol Date: 2004-04 Impact factor: 4.307
Authors: Sam Behjati; Patrick S Tarpey; Kerstin Haase; Hongtao Ye; Matthew D Young; Ludmil B Alexandrov; Sarah J Farndon; Grace Collord; David C Wedge; Inigo Martincorena; Susanna L Cooke; Helen Davies; William Mifsud; Mathias Lidgren; Sancha Martin; Calli Latimer; Mark Maddison; Adam P Butler; Jon W Teague; Nischalan Pillay; Adam Shlien; Ultan McDermott; P Andrew Futreal; Daniel Baumhoer; Olga Zaikova; Bodil Bjerkehagen; Ola Myklebost; M Fernanda Amary; Roberto Tirabosco; Peter Van Loo; Michael R Stratton; Adrienne M Flanagan; Peter J Campbell Journal: Nat Commun Date: 2017-06-23 Impact factor: 14.919
Authors: Anita K Luu; Courtney R Schott; Robert Jones; Andrew C Poon; Brandon Golding; Roa'a Hamed; Benjamin Deheshi; Anthony Mutsaers; Geoffrey A Wood; Alicia M Viloria-Petit Journal: BMC Vet Res Date: 2018-11-26 Impact factor: 2.741